In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| 10-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
Revenues: |
BayMedica | | | 1.4 | | | | | |
Revenues | | | 1.4 | 1.1 | 1.5 | 1.6 | 1.6 | 1.6 |
Revenue growth | | | -11.6% | -31.7% | 103.8% | | | |
Cost of goods sold | | | 0.8 | 0.6 | 0.4 | 0.2 | 0.1 | 0.0 |
Gross profit | | | 0.6 | 0.5 | 1.1 | 1.4 | 1.5 | 1.6 |
Gross margin | | | 44.6% | 42.6% | 75.3% | 85.3% | 95.0% | 100.0% |
Selling, general and administrative [+] | | | 7.3 | 7.2 | 6.7 | 6.1 | 5.2 | 4.5 |
General and administrative | | | 7.3 | 7.2 | 6.7 | 6.1 | 5.2 | 4.5 |
Research and development | | | 7.2 | 7.3 | 7.5 | 7.5 | 5.9 | 5.3 |
Other operating expenses | | | 1.7 | 1.1 | 0.8 | 1.2 | 1.4 | 1.4 |
EBITDA [+] | | | -15.6 | -15.0 | -13.8 | -13.4 | -11.0 | -9.7 |
EBITDA growth | | | 42.1% | 55.8% | 74.0% | | | |
EBITDA margin | | | -1106.9% | -1380.2% | -951.4% | -849.2% | -688.8% | -605.1% |
Depreciation | | | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
EBITA | | | -15.7 | -15.1 | -13.9 | -13.5 | -11.0 | -9.7 |
EBITA margin | | | -1112.3% | -1386.8% | -953.0% | -850.3% | -690.0% | -606.5% |
Amortization of intangibles | | | 0.1 | | 0.1 | 0.1 | 0.1 | 0.1 |
EBIT [+] | | | -15.8 | -15.2 | -14.0 | -13.6 | -11.1 | -9.8 |
EBIT growth | | | 42.4% | 55.8% | 73.4% | | | |
EBIT margin | | | -1121.5% | -1397.2% | -962.5% | -857.7% | -696.4% | -612.7% |
Non-recurring items | | | | 3.5 | | | | |
Interest income | | | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
Interest income | | | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
Other income (expense), net [+] | | | 0.0 | 0.0 | | -0.1 | -0.5 | -0.4 |
Gain (loss) on foreign currency transactions | | | 0.0 | 0.0 | | 0.1 | -0.1 | -0.2 |
Other non-operating income | | | | | | 0.0 | | |
Other | | | | | | 0.0 | | |
Pre-tax income | | | -19.1 | -18.6 | -14.0 | -13.6 | -11.6 | -10.2 |
Income taxes | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | | | -19.1 | -18.6 | -14.0 | -13.6 | -11.6 | -10.2 |
Net margin | | | -1357.1% | -1707.3% | -961.2% | -860.0% | -725.9% | -639.8% |
|
Basic EPS [+] | | | ($4.83) | ($4.81) | ($3.69) | ($2.46) | ($3.22) | ($2.13) |
Growth | | | 50.2% | 125.6% | 159.5% | | | |
Diluted EPS [+] | | | ($4.83) | ($4.81) | ($3.69) | ($2.46) | ($3.22) | ($2.13) |
Growth | | | 50.2% | 125.6% | 159.5% | | | |
|
Shares outstanding (basic) [+] | | | 4.0 | 3.9 | 3.8 | 5.5 | 3.6 | 4.8 |
Growth | | | 10.1% | -19.2% | -37.0% | | | |
Shares outstanding (diluted) [+] | | | 4.0 | 3.9 | 3.8 | 5.5 | 3.6 | 4.8 |
Growth | | | 10.1% | -19.2% | -37.0% | | | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |